Core Viewpoint - The company is utilizing part of its temporarily idle raised funds for cash management to improve efficiency and increase shareholder returns while ensuring that it does not affect the normal operation of fundraising projects [5][14]. Summary by Sections Cash Management Overview - The cash management amount is 290 million RMB, with 150 million RMB used to purchase structured deposits linked to the euro-to-dollar exchange rate from China Minsheng Bank, 75 million RMB for a large-denomination certificate of deposit from China Merchants Bank, and 65 million RMB for a structured deposit linked to gold from Ping An Bank [2][9]. Approval Process - The company held temporary board and supervisory meetings on January 20-22, 2025, to approve the use of up to 700 million RMB of temporarily idle raised funds for cash management, with a validity period of 12 months from the approval date [3][10]. A subsequent meeting on November 20-21, 2025, approved the continued use of up to 500 million RMB for cash management [11]. Purpose of Cash Management - The purpose is to enhance the efficiency of temporarily idle raised funds, reduce financial costs, and increase shareholder returns while ensuring that the fundraising projects and normal operations are not affected [5][14]. Source of Funds - The funds for cash management come from the proceeds of convertible bonds issued to unspecified investors, totaling approximately 1.08 billion RMB, net of issuance costs [7][8]. Impact on the Company - The cash management initiative is expected to improve the efficiency of idle funds and generate investment returns, thereby enhancing the overall performance of the company and benefiting shareholders [14]. The accounting treatment for large-denomination certificates of deposit and structured deposits will be in accordance with relevant accounting standards [14].
南京医药股份有限公司关于公司及子公司使用部分暂时闲置募集资金进行现金管理的进展公告